Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

Hans Salwender, Ahmet Elmaagacli, Maximilian Merz, Kaya Miah, Axel Benner, Mathias Haenel, Christian Jehn, Elias K Mai, Uta Bertsch, Igor W Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Marc S Raab, Steffen P Luntz, Britta Besemer, Markus Munder, Peter Brossart, Stephan FuhrmannHans-Walter Lindemann, Katja Weisel, Jan Duerig, Hartmut Goldschmidt

Onderzoeksoutput: Articlepeer review

3 Citaten (Scopus)
Originele taal-2English
Pagina's (van-tot)3007-3011
Aantal pagina's5
TijdschriftLeukemia
Volume35
Nummer van het tijdschrift10
DOI's
StatusPublished - okt 2021

Bibliografische nota

Funding Information:
Acknowledgements The GMMG-MM5 trial was supported by Cel-gene, Janssen-Cilag, Chugai, and The Binding Site. The GMMG thanks the Koordinierungszentrum für Klinische Studien (KKS) Heidelberg for the support of the trial and data monitoring. The GMMG thanks all participating investigators and centers.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

Citeer dit